While straightforward economics may dictate that a pharmaceutical company’s bottom line is really driven by the need to sell its products for monetary gain, a more holistic view should be taken. The company is in a critical position, market wise in relation to government regulators and the end consumer. There is a complex understanding and relationship between all the main players and pharmaceutical consultants help to emphasise these individual roles, as they disseminate information to help oil all the moving parts of this complex machine.
FDA regulations require pharmaceutical companies to be in strict compliance, make use of established practices and all safety criteria as they produce products for final use. Marketing plays a critical role in this arrangement and is far more than just a means to an end. As the advisor to the consumer, a pharmacist or physician has a lot of input and must satisfy the patient, whilst also adhering to budgetary restrictions, insurance company stipulations and positions.
The direct communication between health care professionals and the pharmaceutical companies through various marketing channels ultimately dictates the efficient delivery of products and services to the end-user, the patient. There is a lot at stake as the patient’s ability to lead a healthy and productive life can be affected by the quality and standard of the marketing trail. Marketing in this environment is most certainly a two-way operation. The company must not only communicate the benefits and risks of its product to the professional, the reasoning and science behind its introduction and instructions for its use, but the professional must give real world feedback and crucial data to the company.
The contribution of pharma consulting should never be underestimated as it can help to emphasise how certain conditions can be treated by emerging products and help to reveal how other illnesses, previously under-served, could be addressed. Where treatment gaps may have previously existed, the research and work done by the pharmaceutical companies can also raise awareness and enable treatment for patients who may not have realised the treatment was available. There is no guarantee that such amazing products may even find their way into the hands of the sufferer. As such, marketing is pivotal in helping to relay this information from the manufacture, through the professional to the end-user.
Scientific breakthroughs enable the creation of products which are subsequently sanctioned by the government and this whole process focuses on the need for treatment of chronic illnesses. For example, certain side effects or by-products of a critical element may not have been apparent, or the link between illness and cure revealed, unless and until adequate marketing channels are open between the researchers, producers, professionals and patients.
Generally, pharmaceutical consulting firms are highly skilled at developing communication between vital parties and educating all players. Their interaction, encouragement and foresight can help to ensure that the marketing machine is primed and key players are aware of each other’s vital contributions, so important in this hyper-competitive environment.
Alan Gillies is the CEO of L2L Consulting, a cutting-edge pharma consultancy firm which specialises in optimising productivity and performance within international companies by applying tailored organisational strategies.
